Novartis AG ADR (NVS)vsSoleno Therapeutics Inc (SLNO)
NVS
Novartis AG ADR
$159.26
+3.60%
HEALTHCARE · Cap: $303.67B
SLNO
Soleno Therapeutics Inc
$53.01
0.00%
HEALTHCARE · Cap: $2.76B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 20027% more annual revenue ($57.36B vs $285.01M). SLNO leads profitability with a 33.7% profit margin vs 17.5%. SLNO trades at a lower P/E of 27.4x. SLNO earns a higher WallStSmart Score of 52/100 (C-).
NVS
Hold48
out of 100
Grade: D+
SLNO
Buy52
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-68.3%
Fair Value
$95.56
Current Price
$159.26
$63.70 premium
Intrinsic value data unavailable for SLNO.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.3%
Generating 5.6B in free cash flow
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 33.6%
Every $100 of equity generates 26 in profit
Areas to Watch
Premium valuation, high expectations priced in
Trading at 8.1x book value
4.7% revenue growth
Grey zone — moderate risk
Moderate valuation
0.0% revenue growth
0.0% earnings growth
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.5% and operating margin at 34.3%.
Bull Case : SLNO
The strongest argument for SLNO centers on Profit Margin, Operating Margin, Return on Equity. Profitability is solid with margins at 33.7% and operating margin at 33.6%.
Bear Case : NVS
The primary concerns for NVS are P/E Ratio, Price/Book, Revenue Growth.
Bear Case : SLNO
The primary concerns for SLNO are P/E Ratio, Revenue Growth, EPS Growth.
Key Dynamics to Monitor
NVS carries more volatility with a beta of 0.47 — expect wider price swings.
NVS is growing revenue faster at 4.7% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
SLNO scores higher overall (52/100 vs 48/100), backed by strong 33.7% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Soleno Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of rare diseases. The company is headquartered in Redwood City, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?